Effect of Polyphenols on Iron Absorption From Finger Millet

December 10, 2019 updated by: Swiss Federal Institute of Technology

An Absorption Study in Young Women to Evaluate the Effect of Polyphenols on Iron Absorption From Ragi (Finger Millet) Using the Iron Isotopic Method

In India, one of the fast growing countries, 53% of all women have anaemia as per the National Family Health Survey. A recently published study on the burden of disease in India concluded that the burden of Iron deficiency anaemia (IDA) is 3 times higher than the average globally for other geographies at a similar level of development, and that women are disproportionately affected. Finger Millet (Eleusine coracana), more commonly known as Ragi, is a type of a millet crop grown in India, is considerably rich in minerals and its micronutrient density is higher than that of the world's major cereal grains: rice and wheat. Ragi also contains different antinutrients such as phytates and polyphenols, which have been known to have an inhibiting effect on the absorption of iron. On an average, white finger millet contains 0.04-0.09% polyphenols and brown varieties have 0.08-3.47%. The dark variety of ragi is the most widely consumed type. The white ragi is the lesser consumed type. However, the levels of polyphenols, which inhibit the absorption of iron, are ten times lower in the white ragi as compared to the dark ragi. Thus, it is important to evaluate the extent of inhibition of the polyphenols on the iron absorption. This information would be beneficial for policy making and promotion of cultivation of the type of ragi that could be most effective for the consumers

Study Overview

Status

Completed

Conditions

Detailed Description

Finger Millet (Eleusine coracana), more commonly known as Ragi, is a type of a millet crop grown in India, including other countries especially in East Africa. Ragi has been perceived as a potential "super cereal" by the United States National Academies being one of the most nutritious among all major cereals. From the nutritional perspective, finger millet is considerably rich in minerals and its micronutrient density is higher than that of the world's major cereal grains: rice and wheat .

Millets (Ragi or finger millet and Jowar or sorghum) were consumed by 59% of rural and 28% of urban population in Karnataka. Ragi consumption was seen predominantly in south Karnataka with 27% of rural and 17% of urban population reporting consumption.

Ragi is the richest source of calcium among cereals with up to 10-fold higher calcium content than brown rice, wheat or maize and three times than that of milk. It is also rich in iron and fiber, making this crop more nutritive as compared to other most commonly used cereals. Finger millet is enriched in the essential amino acids like lysine and methionine which are important in human health and growth but remain absent from most other plant foods . In addition, it also contains useful amounts of the two polyunsaturated fatty acids- linoleic acid and α-linolenic acid , metabolized products of which facilitate normal development of the central nervous system. Despite the well-documented health benefits of finger millet, only a limited progress has been made in context to its nutraceutical applications as functional food. Although, it may have remained underutilized by the general population due to either unawareness or apprehension, its immense potential for enhancing the nutritional and therapeutic attributes by acting as functional food cannot be ignored.

Ragi also contains different antinutrients such as phytates and polyphenols, which have been known to have an inhibiting effect on the absorption of iron. On an average, white finger millet contains 0.04-0.09% polyphenols and brown varieties have 0.08-3.47% . It was found that found proto-catechuic acid (45.0 mg/100 g) is the major free phenolic acid in ragi. In another study of total phenolic compounds in finger millet, it was found to have 85% benzoic acid derivatives (gallic acid, protocatechuic acid, p-hydroxybenzoic acid, vanillic acid, syringic acid) while rest of the fraction were either cinnamic acid derivatives (ferulic acid, trans-cinnamic acid, p-coumaric acid, caffeic acid, sinapic acid) or flavonoids (quercetin, Proanthocyanidins like condensed tannins) . Among bound phenloic acids, ferulic and p-coumaric acid are the major fractions and account for 64-96 and 50-99% of total ferulic and p-coumaric acid content of finger millet grains, respectively.

The dark variety of ragi is the most widely consumed type. The white ragi is the lesser consumed type. However, the levels of polyphenols, which inhibit the absorption of iron, are ten times lower in the white ragi as compared to the dark ragi. Thus, it is important to evaluate the extent of inhibition of the polyphenols on the iron absorption. This information would be beneficial for policy making and promotion of cultivation of the type of ragi that could be most effective for the consumers

The study duration will be 26 days from the first day of the first meal administration till the last blood withdrawal . For each appointment, the participants will spend about 30 minutes at the Human Nutrition Laboratory at ETH Zurich, between 7 and 9 am for breakfast meal consisting of pancakes made out of the ragi. the white ragi meal and the black ragi meal will be extrinsically labelled with isotopes 57 Fe and 58 Fe respectively. The participants will consume the ragi meal as breakfast. The first type of ragi meal will be given for 5 consecutive days,. They will have a weekend break of two days (during which they will resume their usual eating habits). After that, they will consume the second test meal as breakfast for another five consecutive days. Thus, there will be 10 meals in total. The breakfast meals will be consumed between 7 and 9 am together with a glass of 300 mL bottled water after which they have to wait another 3 hours before they can consume anything. The procedure will remain the same for all the days. Participants will always be asked to fast the day before coming for the feeding, that is, no food intake after 8 pm and no beverage intake after midnight the evening before. On day of screening, day 1 and the end point day 26 of the study, blood samples will be collected after an overnight fast for the determination of Hb, PF, CRP and isotopic ratio

Study Type

Interventional

Enrollment (Actual)

22

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Zurich, Switzerland, 8092
        • ETH Zurich, Laboratory of Human Nutrition
    • ZH
      • Zürich, ZH, Switzerland, 8092
        • ETH Zurich, Laboratory of Human Nutrition

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

16 years to 38 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Female, 18 to 40 years old
  • Body weight up to 65 kg
  • Normal Body Mass Index (18.5 - 25 kg/m2)
  • Signed informed consent
  • Plasma ferritin < 25 ng/ml
  • Able to communicate in and comprehend English language
  • Tasted and found the Ragi to be of acceptable taste and confirmed will to consume the test meals if enrolled in the study

Exclusion Criteria:

  • Pregnancy (assessed by a urinary pregnancy test) / intention to become pregnant
  • Lactating up to 6 weeks before study initiation
  • Moderate or severe anaemia (Hb < 9.0 g/dL)
  • Elevated CRP (> 5.0 mg/L)
  • Any metabolic, gastrointestinal, kidney or chronic disease such as celiac disease, diabetes, hepatitis, hypertension, cancer or cardiovascular diseases (according to the participants own statement)
  • Continuous/long-term use of medication during the whole study (except for contraceptives)
  • Consumption of mineral and vitamin supplements within 2 weeks prior to first meal administration
  • Blood transfusion, blood donation or significant blood loss (accident, surgery) within 4 months prior to first meal administration
  • Earlier participation in a study using iron stable isotopes or participation in any clinical study within the last 30 days
  • Participant who cannot be expected to comply with study protocol (e.g. not available on certain study appointments or difficulties with blood withdrawal)
  • Inability to understand the information sheet and the informed consent form due to cognitive or language reasons

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Black Ragi
During one week of the study, participants are to consume pancakes made from the dark variety of ragi.
Pancakes made out of the dark ragi
Experimental: White Ragi
During the second week of the study, participants are to consume pancakes made from the white variety of ragi
Pancakes made out of the white ragi

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Fractional Iron absorption
Time Frame: 26th day of the study
The fractional iron absrption will be compared in predefined comparisons from the two interventions products that are administered to the study participants
26th day of the study
Total Iron Absorption
Time Frame: 26th day of the study
Total iron absorption from the two ragi types will be compared by measuring the total iron absorbed from all the meals in the study
26th day of the study

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Hemoglobin
Time Frame: screening (-1), baseline (day 1), last test meal consumption (day 26)
Iron status marker
screening (-1), baseline (day 1), last test meal consumption (day 26)
Plasma ferritin
Time Frame: screening (-1), baseline (day 1), last test meal consumption (day 26)
Iron status marker
screening (-1), baseline (day 1), last test meal consumption (day 26)
C-Reactive Protein
Time Frame: screening (-1), baseline (day 1), last test meal consumption (day 26)
Inflammation status
screening (-1), baseline (day 1), last test meal consumption (day 26)
Body Iron stores
Time Frame: last test meal consumption (day 26)
Iron status marker
last test meal consumption (day 26)
Soluble transferrin receptor
Time Frame: last test meal consumption (day 26)
Iron status marker
last test meal consumption (day 26)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 4, 2019

Primary Completion (Actual)

November 29, 2019

Study Completion (Actual)

November 29, 2019

Study Registration Dates

First Submitted

November 21, 2019

First Submitted That Met QC Criteria

December 10, 2019

First Posted (Actual)

December 11, 2019

Study Record Updates

Last Update Posted (Actual)

December 11, 2019

Last Update Submitted That Met QC Criteria

December 10, 2019

Last Verified

December 1, 2019

More Information

Terms related to this study

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Iron-deficiency

Clinical Trials on Black Ragi

3
Subscribe